Black Diamond Therapeutics (BDTX) Depreciation & Amortization (CF) (2019 - 2026)
Black Diamond Therapeutics (BDTX) posted Depreciation & Amortization (CF) of $27000.0 for Q1 2026, down 59.09% on a QoQ basis from $66000.0 in Q4 2025, and down 68.97% year-over-year from $87000.0 in Q1 2025.
Black Diamond Therapeutics (BDTX) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $27000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 68.97% year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $265000.0 (down 22.97% YoY) and the FY2025 annual result came in at $325000.0, down 5.25% from the prior year.
- Depreciation & Amortization (CF) was $27000.0 for Q1 2026 at Black Diamond Therapeutics, down from $66000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $129000.0 in Q3 2022 and bottomed at $27000.0 in Q1 2026.
- A 5-year average of $96470.6 and a median of $86000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 557.89% — and 2026, when it tumbled 68.97%.
- Black Diamond Therapeutics' Depreciation & Amortization (CF) stood at $126000.0 in 2022, then tumbled by 31.75% to $86000.0 in 2023, then slipped by 1.16% to $85000.0 in 2024, then fell by 22.35% to $66000.0 in 2025, then sank by 59.09% to $27000.0 in 2026.
- Business Quant data shows BDTX's Depreciation & Amortization (CF) at $27000.0 in Q1 2026, $66000.0 in Q4 2025, and $86000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.20 Mn |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | 27,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27,000.00 |
| Mar 31, 2026 | 27,000.00 |
| Dec 31, 2025 | 66,000.00 |
| Dec 31, 2025 | 66,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Jun 30, 2025 | 86,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Sep 30, 2024 | 86,000.00 |
| Jun 30, 2024 | 86,000.00 |
| Jun 30, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |
| Dec 31, 2023 | 86,000.00 |